To date, there are few studies examining the relation between levels of OPG and BMD in patients with CKD or end-stage renal disease, conditions associated with an increased risk of mineral and bone disorders, or bone loss [15, 36]. This evidence concerns the gene TNFRSF11B and chronic kidney disease.